Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
)'s Infant Nutrition Unit for $11.9 Billion
4/23/2012 6:54:27 AM
Swiss food group Nestle is to buy U.S. drugmaker Pfizer's baby food business for $11.85 billion, beating out French rival Danone in the battle for dominance of fast-growing emerging markets. The world's biggest food company had to dig deeper than expected into its ample pockets to win the high-stakes fight for Pfizer Nutrition, which makes 85 percent of its sales in emerging markets. "The price tag is high, however Nestle is securing a high growth/margin business with high exposure in the emerging markets. China will become the number 3 market for Nestle overall," said Vontobel analyst Jean-Philippe Bertschy.
New York Times
Closing In on
(PFE)'s Baby Formula Biz, May Pay Up to $10 Billion: Report
(RHHBY) Starts Talking to
Mead Johnson Nutrition Company
Combine to Fight
(PFE) Unit - Sources
(NABI) Merges With
Biota Holdings Limited
(BTA.AX) to Create a $250 Million Group;
to Move to the US
Invests €50 Million in 5-year Probiotic Licensing Deal With
Cell Therapeutics, Inc.
(CTIC) Pays $30 Million in Cash and Stock for
’s Selective JAK2 Inhibitor
(PFE)'s Baby Formula Sale is One of Six Events That Will Set the Mood for Pharma Stocks
Aspen Pharmacare Ltd.
(GSK) OTC Drug Brands for $263 Million
(AMGN) to Assume Some Enbrel Sales Work From
(PFE); Declined to Say How Many Employees are Affected -
to Hire the Second Half of 2012
Par Pharmaceutical Companies, Inc.
(PRX) Buys Rights to Market, Distribute Generic Dexilant® in the U.S.
comments powered by Disqus.
comments powered by
New York Times
Biotech/Pharma - Mergers and Acquisitions
Biotech/Pharma - Mergers and Acquisitions (World)